Navigation Links
Stemedica Advances to Phase II Stroke Trial with Lead Product Stemedyne-MSC
Date:7/10/2013

San Diego, CA (PRWEB) July 10, 2013

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today the completion of enrollment and treatment of patients in a Phase I study with Stemedica’s lead product Stemedyne-MSC. These specially formulated ischemic adult allogeneic mesenchymal stem cells have been manufactured at Stemedica’s cGMP compliant facility and have been successfully used to treat patients in an ischemic stroke study: “A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability and Preliminary Treatment Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects with Ischemic Stroke.”

The primary goal of the Phase I study was to assess the safety and tolerability of treatment with Stemedyne-MSC as determined by the incidence and severity of adverse events, clinically-significant changes on clinical laboratory tests, vital signs, physical and neurologic examinations in patients with a clinical diagnosis six months post ischemic stroke. The secondary goal was to assess the clinical effects of treatment on neurologic, functional, and motor deficits.

Fifteen patients were treated in this dose escalation Phase I study. Patients received one dose of Stemedyne-MSC via intravenous administration. An Independent Data Safety Monitoring Board reviewed safety data for subjects including adverse events, laboratory data and vital signs. Based on the review, they unanimously voted for the trial to proceed to Phase II.

Michael Levy, MD, PhD, FACS, the Principle Investigator and John Crawford, MD, Co-Investigator at the University of California, San Diego (UCSD) clinical site commented, “We are optimistic that we will continue to see
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Stemedica Enters into a Global Distribution Agreement with Life Technologies
2. Noted Cardiologist Robert Wilensky to Join Stemedica Cardiology Division Scientific & Medical Advisory Board
3. Stemedica Forms Cardiology Division. Sergey Sikora, PhD Appointed As Division President
4. Stemedica and Scripps to Jointly Investigate Therapeutic Effect of Ischemia Tolerant Mesenchymal Stem Cells (itMSC) and Stem Cell Factors in Lung Injury and Sepsis
5. Dr. Gary Stein, SRO Orthopedic Surgeon, Discusses the Latest Advances and Treatments of Joint Pain
6. American Brain Tumor Association Conference Advances Holistic Approach to Living with a Brain Tumor
7. Tennessee Senate Advances Bill Lowering Requirements for Wearing Helmets on Motorcycles
8. Pace of New Drug Advances May Be Slowing, Study Finds
9. Stem Cell Orthopedic Expand Advances in Sports Medicine
10. Florida Autism Center Advances Autism Treatment through New Staff Training Series
11. Pharmaceutical advances offer new options for health outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... about an increase in adolescents, marijuana use following the ... relief. According to a new study at Rhode Island ... states with and without medical marijuana laws, legalizing the ... The study is published online in advance of print ... , "Any time a state considers legalizing medical marijuana, ...
(Date:4/23/2014)... published in the journal Oncotarget , explored ... appearances or their own DNA signatures within the ... to design effective, targeted treatment strategies. , Firstly ... mutation and either the KRAS or BRAF mutation. ... the EGFR gene mutation have that specific mutation ...
(Date:4/23/2014)... of endogenous neural precursor cells cannot alone compensate ... the perspective of neural plasticity, Dr. Yun Xiang ... observed the effects of functional electrical stimulation treatment ... of basic fibroblast growth factor and epidermal growth ... side. The researchers found that functional electrical stimulation ...
(Date:4/22/2014)... sport in the United States with 1 million participants ... Center for Injury Research and Policy at Nationwide Children,s ... occurrence and distribution patterns of basketball-related injuries treated in ... among adolescents and teens. , The study, published online ... data relating to adolescents 13-19 years of age who ...
(Date:4/22/2014)... A recently FDA-approved device has been shown to reduce ... as 50 percent. When coupled with an innovative electrode ... device facilitated the complete elimination of seizures in nearly ... decade-long clinical trials. , That,s good news for a ... U.S. living with epilepsy whose seizures can,t be controlled ...
Breaking Medicine News(10 mins):Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2
... ... staggeringly researched book, A Terrible Mistake: The Murder of Frank Olson and the CIA’s Secret ... with LSD and other drugs in a series of biochemical experiments. , ... (Vocus) November 11, 2009 -- Most Americans remember ...
... ... trained to perform the latest minimally invasive single as well as double hip replacement procedures. ... (Vocus) June 29, 2009 ... Center as the 135-year-old downtown hospital,s Medical Director of Joint Replacement and Reconstruction, Dr. ...
... , ... knowledge, relocation management, and design services, Ms. McKenna and the Beyond the Box team can ... “aging in place. , ... November 11, 2009 -- The Washington, DC based relocation and design firm, Beyond the ...
... LONDON, November 11 It,s official, everyone ... from,British Lion Eggs stated that 6 out of 10 women will ... in order to look their very,shimmering best! , ... last pounds, and,still ensure you,re on tip top form. Here,s the ...
... , CHARLOTTE, N.C., Nov. 10 Anthony Asher, MD, ... NC, has co-authored the first evidence-based, multidisciplinary treatment guidelines ... at the Congress of Neurological Surgeons 2009 Annual Meeting ... year by a 20-member panel from various medical specialties. ...
... ... -- "What I,ve Learned About the Throwing Arm in the Last 30 Years" , ... Gulf Breeze, Fla. (Vocus) November 10, ... Institute will hold its inaugural Grand Rounds presentation on November, 19, 2009 at 5:30 ...
Cached Medicine News:Health News:Explosive New Book Exposes the CIA, LSD Experiments and Murder 2Health News:Explosive New Book Exposes the CIA, LSD Experiments and Murder 3Health News:Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center 2Health News:Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center 3Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 2Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 3Health News:realbuzz.com Top Tips to Cut the Calories This Christmas Party Season 2Health News:Local Neurosurgeon Co-Authors National Treatment Guidelines for Brain Tumor Patients 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 3
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Easy-On Knee Brace features an adjustable ... 0to 135 in 10 increments. Adjust ... to expose the stop pins and ... thick, self-padded washable fabric with Velcro ...
... BODI™ Dynamic Orthosis is the dynamic ... application over time is proven effective in ... half the time of other therapies. Can ... Orthosis.,Indications: For all joint stiffness and soft ...
... Band uses an aircell to ... tendon helping to relieve symptoms ... tendonitis. Focusing the pressure decreases ... with less constriction of the ...
... Provides shoulder ... range of motion ... rotator cuff tears, ... The shoulder brace ...
Medicine Products: